Skip to main content

Research Repository

Advanced Search

Plasma cells: a feasible therapeutic target in pulmonary fibrosis?

Goodwin, Amanda T.; Noble, Paul W.; Tatler, Amanda L.

Authors

AMANDA GOODWIN Amanda.Goodwin2@nottingham.ac.uk
Clinical Assistant Professor (Nihr Clinical Lecturer in Respiratory Medicine)

Paul W. Noble

AMANDA TATLER AMANDA.TATLER@NOTTINGHAM.AC.UK
Principal Research Fellow



Abstract

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease characterised by the irreversible replacement of normal lung parenchyma with stiff scar tissue. The prognosis of IPF is very poor, with a median survival worse than many cancers at 2–3 years, and this condition is associated with increasing incidence and mortality rates worldwide [1–4]. Despite a dramatic increase in IPF clinical trials over the past 20 years, there remain only two therapies approved for use in IPF: nintedanib and pirfenidone [5, 6]. These antifibrotic drugs are not curative, do not improve patient symptoms or functional status and only slow down loss of lung function. Therefore, work to understand the key cells and molecular pathways that drive IPF is essential to identify new therapies for this devastating disease.

Citation

Goodwin, A. T., Noble, P. W., & Tatler, A. L. (2022). Plasma cells: a feasible therapeutic target in pulmonary fibrosis?. European Respiratory Journal, 60(5), Article 2201748. https://doi.org/10.1183/13993003.01748-2022

Journal Article Type Article
Acceptance Date Sep 17, 2022
Online Publication Date Nov 24, 2022
Publication Date Nov 24, 2022
Deposit Date Dec 18, 2022
Journal European Respiratory Journal
Print ISSN 0903-1936
Electronic ISSN 1399-3003
Publisher European Respiratory Society
Peer Reviewed Peer Reviewed
Volume 60
Issue 5
Article Number 2201748
DOI https://doi.org/10.1183/13993003.01748-2022
Keywords Pulmonary and Respiratory Medicine
Public URL https://nottingham-repository.worktribe.com/output/14040527
Publisher URL https://erj.ersjournals.com/content/60/5/2201748